Citius Pharmaceuticals Inc., of Cranford, N.J., said it closed its at-the-market offering of about 7.8 million shares and common warrants to purchase up to an aggregate of 7.8 million shares, sold at $0.8951 per share and warrant. Read More
Avanir Pharmaceuticals Inc., of Aliso Viejo, Calif., said it reached a resolution of civil, criminal and administrative claims with the federal government and participating state authorities. Read More
Relmada Therapeutics Inc., of New York, said its board approved a 1-for-4 reverse stock split in preparation for its proposed listing of its common stock on Nasdaq. Read More
SUZHOU, China – Under the "Healthy China" campaign, China has introduced a three-year action plan for preventing and treating cancer. The plan vows to speed up the marketing of cancer drugs in the country, even aiming for simultaneous marketing with other countries. Read More
BARCELONA, Spain – This year's theme at the European Society for Medical Oncology's (ESMO) 2019 annual meeting is "translating science into better patient care." Read More
PERTH, Australia – Australia is at risk of falling behind the U.S. and Europe in preventing recurrence of melanoma, the Melanoma Institute Australia warns. It is urging the Australian government to undertake a timely review of immunotherapy treatments effective in preventing the spread of melanoma and to fast track listings on the government-subsidized Pharmaceutical Benefits Scheme (PBS). Read More
Aravive Inc.'s chief medical officer, Gail McIntyre, told BioWorld that a "very clever mechanism" designed by researchers at Stanford University helped lead to positive data from the first 12 patients of the ongoing phase Ib part of the phase Ib/II experiment with AVB-500 against notoriously hard-to-beat ovarian cancer. Read More
Pfizer Inc. edged closer to Dermira Inc. in the rush for an approved treatment for atopic dermatitis (AD), a field dominated by Regeneron Pharmaceutical Inc.'s FDA-approved blockbuster, Dupixent (dupilumab), as Pfizer reported positive top-line results from a phase III trial evaluating the efficacy and safety of its oral JAK1 inhibitor, abrocitinib. Read More
LONDON – Preparations for a no-deal Brexit are intensifying, with the government repeatedly saying the U.K. will leave on Oct. 31, and little sign that an agreement on an orderly exit will be reached by then. The U.K. Bioindustry Association (BIA) has stepped up its efforts to help members prepare, planning a series of events around the country and switching from monthly to weekly webinars, to provide up-to-date guidance in what is a fluid situation. Read More
Despite the fact that antidepressants are taken by more than 10% of the U.S. population, large randomized controlled trials have found little evidence that they are beneficial. However, anecdotal evidence suggests that some patients benefit strongly. Read More
